Peng M, Yang X, Wang Y, Zhou L, Ge F, Liu S, Liu W, Cheng L, Wang K. Clinical combined PET/CT radiomics model prediction of benefit from platinum-based chemotherapy and chemoradiotherapy in patients with small cell lung cancer.
Nucl Med Commun 2025:00006231-990000000-00411. [PMID:
40084524 DOI:
10.1097/mnm.0000000000001971]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/16/2025]
Abstract
OBJECTIVE
To develop and validate a clinical combined radiomics model for predicting the treatment response and long-term survival prognosis of small cell lung cancer (SCLC) patients receiving platinum-based chemotherapy, as well as survival outcomes following chemoradiotherapy.
METHODS
A total of 98 SCLC patients treated with platinum-based first-line chemotherapy were included in this study. Five prediction models for assessing the short-term efficacy of platinum-based first-line chemotherapy were developed using a logistic regression algorithm. The performance of the models was assessed by calculating the area under the curve of the receiver operating characteristic curves. For predicting progression-free survival (PFS) and overall survival in the platinum-based chemotherapy group and the chemoradiotherapy group, the optimal cutoff value was determined using X-tile software. Kaplan-Meier survival curves were plotted, and the log-rank test was used to compare survival outcomes.
RESULTS
Among the five models for predicting short-term efficacy, the clinical combined positron emission tomography/computed tomography (PET/CT) radiomics model performed the best, achieving areas under the curve of 0.832 and 0.833 for the training and test sets, respectively. The Kaplan-Meier survival analysis indicated that both the high-scoring Combine group and high-scoring PET/CT group were significantly associated with worse PFS and worse overall survival in the platinum-only chemotherapy group. Additionally, the high-scoring CT group was significantly associated with worse PFS in the chemoradiotherapy group.
CONCLUSION
The clinical combined PET/CT radiomics model can noninvasively and accurately predict the response to platinum-based treatments in SCLC as well as long-term survival prognosis, which can contribute to personalized treatment strategies and guide precision therapy for SCLC patients.
Collapse